191028-25-8

Basic information

• Product Name: N-(5-bromo-1H-benzo[d]imidazol-2-yl)acetamide
• Synonyms: N-(5-bromo-1H-benzo[d]imidazol-2-yl)acetamide
• CAS NO: 191028-25-8
• Molecular Formula: C₉H₈BrN₃O
• Molecular Weight: 254.08332
• EINECS: -0
• Mol File: 191028-25-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(5-bromo-1H-benzo[d]imidazol-2-yl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-bromo-1H-benzo[d]imidazol-2-yl)acetamide(191028-25-8)
• EPA Substance Registry System: N-(5-bromo-1H-benzo[d]imidazol-2-yl)acetamide(191028-25-8)

Safety Data

• Hazardous Substances Data: 191028-25-8(Hazardous Substances Data)

Upstream product

• 1575-37-7 4-Bromo-benzene-1,2-diamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 108-24-7 acetic anhydride 
• 791595-74-9 5-bromo-1H-benzo[d]imidazol-2-amine 
• 75-36-5 acetyl chloride 

Downstream Products

• 1162680-38-7 N-(5-(6-chloro-5-(4-fluorophenylsulfonamido)pyridin-3-yl)-1H-benzo[d]imidazol-2-yl)acetamide 
• 1416335-30-2 N-(6-(5-(2,4-difluorophenylsulfonamido)-6-methoxypyridin-3-yl)-1H-benzo[d]imidazol-2-yl)acetamide 

Relevant articles and documents

Discovery of Potent and Selective PI3KγInhibitors

The selective inhibition of the lipid signaling enzyme PI3Kγconstitutes an opportunity to mediate immunosuppression and inflammation within the tumor microenvironment but is difficult to achieve due to the high sequence homology across the class I PI3K isoforms. Here, we describe the design of a novel series of potent PI3Kγinhibitors that attain high isoform selectivity through the divergent projection of substituents into both the selectivity and alkyl-induced pockets within the adenosine triphosphate (ATP) binding site of PI3Kγ. These efforts have culminated in the discovery of 5-[2-amino-3-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-5-yl]-2-[(1S)-1-cyclopropylethyl]-7-(trifluoromethyl)-2,3-dihydro-1H-isoindol-1-one (4, IC50 = 0.064 μM, THP-1 cells), which displays >600-fold selectivity for PI3Kγover the other class I isoforms and is a promising step toward the identification of a clinical development candidate. The structure-activity relationships identified throughout this campaign demonstrate that greater γ-selectivity can be achieved by inhibitors that occupy an alkyl-induced pocket and possess bicyclic hinge-binding motifs capable of forming more than one hydrogen bond to the hinge region of PI3Kγ.

HSD17B13 INHIBITORS AND USES THEREOF

Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH,

N-arylation of protected and unprotected 5-bromo-2-aminobenzimidazole as organic material: Non-linear optical (nlo) properties and structural feature determination through computational approach

The interest in the NLO response of organic compounds is growing rapidly, due to the ease of synthesis, availability, and low loss. Here, in this study, Cu(II)-catalyzed selective N-arylation of 2-aminobenzimidazoles derivatives were achieved in the presence of different bases Et3N/TMEDA, solvents DCM/MeOH/H2O, and various aryl boronic acids under open atmospheric conditions. Two different copper-catalyzed pathways were selected for N-arylation in the presence of active nucleophilic sites, providing a unique tool for the preparation of NLO materials, C-NH (aryl) derivatives of 2-aminobenzimidazoles with protection and without protection of NH2 group. In addition to NMR analysis, all synthesized derivatives (1a–1f and 2a–2f) of 5-bromo-2-aminobenzimidazole (1) were computed for their non-linear optical (NLO) properties and reactivity descriptor parameters. Frontier molecular orbital (FMO) analysis was performed to get information about the electronic properties and reactivity of synthesized compounds.

MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF

Selective mTOR inhibitors of formulas (I)-(III), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from abnormal cell growth, functions, or behaviors mediated by an mTOR kinase and/or one or more PI3K enzyme, are provided. Such diseases and disorder include cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

BENZIMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS

Provided are compounds of Formulas I, II, III, IV, V, and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

Structure-activity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: Investigations of various 6,5-heterocycles to improve metabolic stability

N-(6-(6-Chloro-5-(4-fluorophenylsulfonamido)pyridin-3-yl)benzo[d] thiazol-2-yl)acetamide (1) is a potent and efficacious inhibitor of PI3Kα and mTOR in vitro and in vivo. However, in hepatocyte and in vivo metabolism studies, 1 was found to undergo deacet

BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE

The invention is directed to Compounds of Formula (I): the invention provides compounds that inhibit, regulate, and/or modulate P13K and/or mTOR that are useful in the treatment of hyperproliferative diseases, such as cancer, in mammals. This invention al

Inhibitors of PI3 kinase

The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof, that inhibit phosphoinositide 3-kinase; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds.

1-Aza-1',3'-diaza-3,3'-sigmatropic rearrangements - A convenient synthesis of benzimidazole derivatives

1-Aryl-2-acyl-2-cyanohydrazines undergo smooth thermal rearrangements to provide 2-aminoacylbenzimidazoles in excellent yields. A short synthesis of the highly mutagenic dietary amine, IQ, is reported.